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 Abstract
Epilepsy is one of the most common neurologic disorders. The epileptic seizures as well as antiepileptic drugs 
may disturb the reproductive system function. Polycystic ovary syndrome occurs more commonly in women with 
epilepsy, either treated or not with valproic acid. This article discusses the current knowledge about the relationships 
between epilepsy and polycystic ovary syndrome. 
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 Streszcznie
Padaczka jest jedną z najczęstszych chorób neurologicznych. Zarówno napady padaczkowe, jak i stosowane w 
tej chorobie leki mogą zaburzać czynność układu rozrodczego. Zespół wielotorbielowatych jajników występuje 
częściej zarówno u nieleczonych, jak i leczonych kwasem walproinowym kobiet z padaczką. Artykuł przedstawia 
aktualny stan wiedzy na temat związków pomiędzy oboma schorzeniami.
 Słowa kluczowe: zespół wielotorbielowartych jajników (PCOS) / padaczka / 
      / kwas walproinowy / 
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2.	 clinical	 and/or	 biochemical	 features	 of	 hyperandrogenism,	
3.	presence	of	the	characteristic	features	of	the	ovaries	in	ultra-
sonography	(polycystic	ovaries	 -	PCO).	Other	diseases	such	as	










and	polycystic	ovary	 syndrome.	Herzog	has	 shown	 that	PCOS	






seizures	 throughout	 the	middle	 temporal	area	(medial	 temporal	
areas)	stimulate	the	secretion	of	GnRH	(gonadotropin-releasing	















the	 left	 temporal	 lobe	would	be	 associated	with	PCOS,	 and	 in	
the	right	temporal	lobe	with	the	occurrence	of	hypogonadotropic	


































ment	 of	 epilepsy.	Drugs	 such	 as	 carbamazepine,	 phenobarbital	
or	 phenytoin	 increase	 the	 activity	 of	 hepatic	 cytochrome	P450	
involved	 in	 steroid	 hormone	metabolism	 and	 increase	 the	 pro-




















hyperandrogenemia,	weight	 gain,	 hyperinsulinemia	 and	 insulin	
resistance	[13].
VPA	 is	a	 short-chain	 fatty	acid,	which	acts	 throughout	 the	
GABA-ergic	 (GABA	 γ-aminobutyric	 acid)	 and	 sodium	 chan-
nel	activity.	Its	impact	on	cell	function	is	also	being	postulated.	




of	 transcription	 factors.	VPA	 reversibly	 inhibits	 the	 activity	 of	
histone	deacetylases	class	 I	and	consequently	 increases	histone	
acetylation,	which	alters	the	expression	of	selected	genes	[15].
Nelson	DeGrave	et	 al.,	 studied	 the	 effect	of	various	doses	
of	VPA	on	steroidogenic	enzymes	activity	in	thecal	cell	cultures	
obtained	 after	 hysterectomy	 from	women	with	 normal	 ovaries	
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and	 PCOS	 [8].	 VPA	 in	 pharmacological	 doses	 (500uM)	 was	
found	to	increase	synthesis	of	androgens	(dehydroepiandroster-






















interfere	 with	 the	 hypothalamic-pituitary-gonadal	 axis	 through	
the	influence	on	GnRH	pulse	generator	[16].
2) Induction of hyperleptinemia and resistance to leptin




This	 is	 supported	by	 several	 facts.	First,	 slim	patients	who	are	
taking	VPA	do	not	show	elevated	levels	of	leptin.	Secondly,	there	
is	no	 significant	difference	 in	 levels	of	 leptin	 in	obese	patients	
taking	VPA	and	in	the	obese	control	group.	Thirdly,	in	a	group	







3) Effects on adiponectin
It	was	shown	that	 the	use	of	VPA	is	associated	with	lower	
levels	of	adiponectin,	but	only	in	people	who	experienced	weight	










the	 control	group.	 In	 addition,	higher	 concentrations	of	 insulin	
was	also	observed	after	glucose	load	[20].	In	another	study	Pyl-
vänen	and	colleagues	have	shown	that	both	lean	and	obese	indi-
viduals	using	VPA	had	elevated	 insulin	 levels	 [21].	The	use	of	
VPA	is	associated	with	 increased	fasting	 insulin	 levels,	but	not	
with	increased	levels	of	proinsulin	and	C-peptide	in	the	fasting	
state,	suggesting	that	the	drug	has	no	effect	on	insulin	secretion,	

















weight	 was	 the	 same.	 In	 four	 pairs	 of	 twins	 weight	 gain	 was	
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